A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group. • Arctic Health

It appears no script is enabled within your browser. Please enable JavaScript to use this site.

Home

View Selections: 0 Items Help

A phase II trial of DuP 937 (Teloxantrone) in non-small cell lung cancer. A study of the NCIC Clinical Trials Group.

https://arctichealth.org/en/permalink/ahliterature220434

Source: Ann Oncol. 1993 Sep;4(8):693-4

Publication Type: Article

Date: Sep-1993

Author: R W Gregg; L. Kaizer; S. Fine; K. Gelmon; G. Wielgosz; E. Eisenhauer

Author Affiliation: Department of Radiation Oncology, Dalhousie University, Halifax, N.S., Canada.

Source: Ann Oncol. 1993 Sep;4(8):693-4

Date: Sep-1993

Language: English

Publication Type: Article

Keywords: Aged; Anthraquinones - administration & dosage - adverse effects - therapeutic use; Antineoplastic Agents - administration & dosage - adverse effects - therapeutic use; Canada; Carcinoma, Non-Small-Cell Lung - drug therapy; Female; Humans; Lung Neoplasms - drug therapy; Male; Middle Aged; Neutropenia - chemically induced; Pyrazoles - administration & dosage - adverse effects - therapeutic use

PubMed ID: 8241002 View in PubMed